N.J. hospital accused of false advertising, questionable business practices

Meadowlands Hospital Medical Center (MHMC) in Seacaucus, New Jersey, has been the subject of an investigative series from NJ Spotlight, accusing the facility of lying about the quality of its services and having a long record of safety violations.

The three-article series first focused on the hospital’s “AmeriMama program,” which offers tour packages to Russian women to give birth at the hospital, making their children eligible for dual citizenship. While so-called “birth tourism” isn’t illegal, the series alleged MHMC falsely promoted its neonatal division as one of the best in the country, when it’s actually been ranked below national benchmarks.

In a separate article on questionable business practices, NJ Spotlight said MHMC has been accused of safety violations such as poorly tracking medical mistakes, not throwing away expired food and deteriorating building conditions.

The third part of the series dealt with the political dealings of the hospital’s owners, including $300,000 in contributions to current New Jersey Gov. Chris Christie.

To read the series from the beginning, click on the link below: 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.